| TA98 |
Attention deficit hyperactivity disorder (ADHD) - methylphenidate, atomoxetine and dexamfetamine (review) (TA98) |
|
-
-
Methylphenidate, atomoxetine and dexamfetamine for the treatment of attention deficit hyperactivity disorder in children and adolescents (including a review of guidance TA13)
If a child or adolescent needs treatment with medication for ADHD, methylphenidate, atomoxetine and dexamfetamine are all recommended as possible choices. When deciding which to use, doctors should consider the following:
- whether the child or adolescent has other conditions such as epilepsy
- the side effects of each medicine
- factors that might make it difficult for the person to take the medicine at the right time (for example, if it is difficult to take a dose during school hours)
- the possibility that the medicine might be misused, or passed on to another person for misuse
- the individual preference of the child or adolescent and/or their family or carer.
Where more than one of the medicines is considered to be appropriate for a child or adolescent, their doctor should choose the cheapest one.
Treatment with methylphenidate, atomoxetine or dexamfetamine should only be started after a specialist who is an expert in ADHD has thoroughly assessed the child or adolescent and confirmed the diagnosis. Once treatment has been started it can be continued and monitored by a GP.
-
Other information
How this guidance was produced
Background information
- Review decision: May 2012
- TA98 Attention deficit hyperactivity disorder (ADHD) - methylphenidate, atomoxetine and dexamfetamine (review): review proposal
- NICE issues guidance on drug treatments for attention deficit hyperactivity disorder (ADHD)
- Appeal panel decision - Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents
- Assessment report: Attention deficit hyperactivity disorder - methylphenidate, atomoxetine and dexamfetamine (review)
- Review decision - May 2009
- Review proposal - March 2009
This page was last updated: 22 May 2012
-
Guidance formats
Attention deficit hyperactivity disorder (ADHD) - methylphenidate, atomoxetine and dexamfetamine (review)
Guideline for patients and carers (PDF)
-
Implementation tools and resources
See this guidance in practice
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
